- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/55 - IL-2
Patent holdings for IPC class C07K 14/55
Total number of patents in this class: 1813
10-year publication summary
|
51
|
81
|
129
|
142
|
243
|
218
|
212
|
226
|
180
|
117
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Cue Biopharma, Inc. | 206 |
71 |
| The Board of Trustees of the Leland Stanford Junior University | 6656 |
45 |
| Immunitybio, Inc. | 506 |
34 |
| Hoffmann-La Roche Inc. | 3796 |
30 |
| Amgen Inc. | 4429 |
26 |
| Regeneron Pharmaceuticals, Inc. | 4727 |
26 |
| Cancer Research Technology Limited | 515 |
25 |
| Tusk Therapeutics Ltd | 31 |
25 |
| Medicenna Therapeutics Inc. | 44 |
24 |
| GI Innovation, Inc. | 60 |
23 |
| Xilio Development, Inc. | 53 |
23 |
| Werewolf Therapeutics, Inc. | 65 |
22 |
| F. Hoffmann-La Roche AG | 7819 |
21 |
| University of Washington | 2447 |
20 |
| Deka Biosciences, Inc. | 43 |
20 |
| Askgene Pharma, Inc. | 52 |
17 |
| Pandion Operations, Inc. | 36 |
17 |
| Anwita Biosciences, Inc. | 28 |
16 |
| Delinia, Inc. | 63 |
15 |
| Bright Peak Therapeutics AG | 60 |
15 |
| Other owners | 1298 |